SCHEMBL17809647

SCHEMBL17809647

Cc1cncc(-c2cc3c(cc2C#N)N(C)CCC3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 8/20 0.40
CYP11B1 P15538 3/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
CASP1 P29466 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LRRK2 Q5S007 4/20 0.39
USP30 Q70CQ3 2/20 0.36
EED O75530 1/20 0.35
RBBP4 Q09028 1/20 0.35
SUZ12 Q15022 1/20 0.35
EZH2 Q15910 1/20 0.35
AEBP2 Q6ZN18 1/20 0.35
TP53 P04637 1/20 0.34
CYP2A6 P11509 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809650 0.86 ALDH1A1 (0.41) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17806323 0.85 CYP11B2 (0.38) CYP11B2CYP11B1LRRK2USP30EED
SCHEMBL17809672 0.82 CYP11B2 (0.45) CYP11B2CYP11B1ALDH1A1HSD17B10
SCHEMBL17809667 0.81 KDM4E (0.41) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17809629 0.80 USP30 (0.53) KDM4EALDH1A1GAAHPGDGLA
SCHEMBL17809654 0.80 CYP11B2 (0.41) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17809652 0.77 LRRK2 (0.40) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17809787 0.77 CYP11B2 (0.41) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17794997 0.77 CYP11B2 (0.39) CYP11B2CYP11B1KDM4EALDH1A1GAA
SCHEMBL17795005 0.77 KDM4E (0.39) CYP11B2CYP11B1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885CYP11B1 1468/4885KDM4E 465/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885CYP11B1 1468/4885KDM4E 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.